Project Grant R21CA317034
Award Date 6/8/26
Completion Date 5/31/28
Dollars Obligated $437K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital (the awardee) a Project Grant of $682,140 on June 4, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate the SPIDER (Synthetic Potentiated Immunogenic Depot Engaged by Radiation) platform for treating locally advanced non-small cell lung cancer (NSCLC). The deliverables include the development of radiation-responsive nanoparticles capable of...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Project Grant Award Summary Massachusetts Eye and Ear Infirmary received a $642,406 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop blood-based early detection methods for viral precancers. The research, which commenced June 1, 2026 and extends through May 31, 2031, will focus on advancing liquid biopsy technologies that detect circulating cell-free viral deoxyribonucleic acid (cfDNA) to identify...
- Federal Project Grant Award Summary The National Cancer Institute awarded Harvard College's Office for Sponsored Programs a $604,102 Project Grant on May 1, 2026, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop innovative three-dimensional (3D) bioprinted vascular cancer models for immunotherapy research. Over the five-year project period (through April 30, 2031), the research will deliver preclinical models that enable study of T cell trafficking,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.602M Project Grant award from the National Institute of Environmental Health Sciences under the Medical Library Assistance program (CFDA 93.879) effective September 1, 2025, through August 31, 2029. The project focuses on developing computational methods for analyzing multiplex immunofluorescence (MIF) imaging data of the tumor microenvironment. The research leverages a clinically validated MIF dataset encompassing...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Broad Institute, Inc. a Project Grant of $742,382 under the Cancer Treatment Research program (CFDA 93.395) beginning June 1, 2026 and concluding May 31, 2031. This award funds research to investigate novel combination immunotherapy approaches for head and neck squamous cell carcinoma (HNSCC). The research focuses on developing and evaluating the synergistic efficacy of protein tyrosine phosphatase non-receptor type 2...